Alterity Therapeutics Ltd Share Price Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 8.37Cr 7.23Cr 6.79Cr 6.18Cr 12Cr 800.29Cr 12Cr 80Cr 31Cr 400.76Cr 31Cr 31Cr 1.33TCr | P/E 2026 * |
-0.42x | P/E 2027 * | -0.42x |
|---|---|---|---|---|---|
| Enterprise Value | 3.85Cr 3.33Cr 3.13Cr 2.84Cr 5.34Cr 368.18Cr 5.43Cr 37Cr 14Cr 184.37Cr 14Cr 14Cr 612.7Cr | EV / Sales 2026 * |
11.7x | EV / Sales 2027 * | 17.1x |
| Free-Float |
91.85% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Macnish
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 8.22Cr | |
| -1.78% | -1.68% | +1.99% | +13.84% | 4.92TCr | |
| -0.16% | -1.42% | +461.45% | +574.12% | 4.33TCr | |
| -2.75% | -0.56% | +11.83% | +69.66% | 4.05TCr | |
| -1.63% | -0.20% | +25.78% | +8.22% | 3.98TCr | |
| -0.50% | +3.08% | +19.91% | +47.26% | 3.27TCr | |
| -0.06% | -3.48% | - | - | 1.62TCr | |
| -0.26% | -1.47% | +26.88% | +119.10% | 1.62TCr | |
| +0.49% | +0.92% | +4.32% | +22.16% | 1.4TCr | |
| -1.51% | +3.87% | +78.33% | +28.09% | 1.34TCr | |
| Average | -0.63% | +2.15% | +78.81% | +110.31% | 2.95TCr | |
| Weighted average by Cap. | -1.18% | +2.54% | +95.45% | +131.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 32.9L 28.42L 26.7L 24.29L 45.66L 31Cr 46.41L 3.13Cr 1.22Cr 16Cr 1.24Cr 1.21Cr 52Cr | 25.04L 21.63L 20.33L 18.49L 34.75L 24Cr 35.33L 2.38Cr 93.12L 12Cr 94.03L 91.99L 40Cr |
| Net income | -1.48Cr -1.27Cr -1.2Cr -1.09Cr -2.05Cr -141.05Cr -2.08Cr -14Cr -5.48Cr -71Cr -5.54Cr -5.42Cr -234.73Cr | -3Cr -2.59Cr -2.43Cr -2.21Cr -4.16Cr -286.54Cr -4.23Cr -28Cr -11Cr -143.49Cr -11Cr -11Cr -476.83Cr |
| Net Debt | -4.52Cr -3.9Cr -3.67Cr -3.34Cr -6.27Cr -432.1Cr -6.37Cr -43Cr -17Cr -216.38Cr -17Cr -17Cr -719.07Cr | -4.09Cr -3.53Cr -3.32Cr -3.02Cr -5.67Cr -390.92Cr -5.77Cr -39Cr -15Cr -195.76Cr -15Cr -15Cr -650.54Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
